Drug development in schizophrenia: Are glutamatergic targets still worth aiming at?

Current Opinion in Psychiatry

Volumn 28, Issue 3, 2015, Pages 207-215

  Goff, Donald C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

glutamate; mGluR5; N methyl D aspartate; schizophrenia

Indexed keywords

AMPA RECEPTOR; CYCLOSERINE; DOPAMINE; GLUTAMATE RECEPTOR; GLYCINE; LAMOTRIGINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHODIESTERASE INHIBITOR; RECEPTOR SUBTYPE; AMINO ACID RECEPTOR AFFECTING AGENT; GLUTAMIC ACID; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; TRIAZINE DERIVATIVE;

ALLOSTERISM; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PROTEIN TARGETING; PROVOCATION TEST; REVIEW; SCHIZOPHRENIA; AGONISTS; DRUG EFFECTS; METABOLISM; REPRODUCIBILITY;

EXCITATORY AMINO ACID AGENTS; GLUTAMIC ACID; HUMANS; RECEPTORS, AMPA; RECEPTORS, METABOTROPIC GLUTAMATE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; TRIAZINES;

EID: 84926313738     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000152     Document Type: Review

References (118)

1. Janowsky D, El-Yousef M, Davis J, et al. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973; 28: 185-191.
2. Seeman P, Lee T, Chau-Wong M. Antipsychotic drug doses and neuroleptic/ dopamine receptors. Nature 1976; 261: 717-719.
3. Davis K, Kahn R, Ko G, DavidsonM. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474-1486.
4. Gupta M, Kaur H, Jajodia A, et al. Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia. Curr Mol Med 2011; 11: 732-743.
5. Rosell DR, Zaluda LC, McClure MM, et al. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology 2015; 40: 446-453.
6. Luby ED, Cohen BD, Rosenbaum G, et al. Study of a new schizophrenomimetic drug-sernyl. AMA Arch Neurol Psychiatry 1959; 81: 363-369.
7. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13: 272-276.
8. Javitt D, Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
9. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
10. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
11. Jentsch J, Roth R. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-225.
12. Grotta J, Clark W, Coull B, et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke 1995; 26: 602-605.
13. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limibic blood flow in schizophrenia. Neuroreport 1995; 6: 869-872.
14. Malhotra A, Adler C, Kennison S, et al. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997; 42: 664-668.
15. Gozzi A, Large CH, Schwarz A, et al. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008; 33: 1690-1703.
16. Anand A, Charney DS, Oren DA, et al. Attentuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry 2000; 57: 270-276.
17. Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2005; 179: 303-309.
18. de Paulis T. M-100907 (Aventis). Curr Opin Investig Drugs 2001; 2: 123-132.
19. Javitt DC, Balla A, Sershen H, Lajtha A. Reversal of the behavioral and neurochemical effects of phencylidine by glycine and glycine transport inhibitors. Biol Psychiatry 1999; 45: 668-679.
20. Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 2007; 21: 283-301.
21. Hwang R, Souza RP, Tiwari AK, et al. Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics 2011; 12: 277-291.
22. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51: 7-61.
23. Jantzie LL, Talos DM, Jackson MC, et al. Developmental expression of N-methyl-D-aspartate (NMDA) receptor subunits in human white and gray matter: potential mechanism of increased vulnerability in the immature brain. Cereb Cortex 2013; 25: 482-495.
24. Cross-Disorder Group of the Psychiatric Genomics Consortium.. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381: 1371-1379.
25. Bard L, Groc L. Glutamate receptor dynamics and protein interaction: lessons from the NMDA receptor. Mol Cell Neurosci 2011; 48: 298-307.
26. Nakazawa K, Zsiros V, Jiang Z, et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012; 62: 1574-1583.
27. Belforte JE, Zsiros V, Sklar ER, et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010; 13: 76-83.
28. Gonzalez-Burgos G, Lewis DA. NMDA receptor hypofunction, parvalbuminpositive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull 2012; 38: 950-957.
29. Wang HX, Gao WJ. Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology 2009; 34: 2028-2040.
30. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-11500.
31. Rotaru DC, Yoshino H, Lewis DA, et al. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. J Neurosci 2011; 31: 142-156.
32. Kocsis B. Differential role of NR2A and NR2B subunits in N-methyl-Daspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry 2012; 71: 987-995.
33. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamineinduced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000; 48: 627-640.
34. Lynch DR, Guttmann RP. Excitotoxicity: perspectives based on N-methyl-Daspartate receptor subtypes. Journal Pharmacol Exp Ther 2002; 300: 717-723.
35. Handelmann G, Nevins M, Mueller L, et al. Milacemide, a glycine pro-drug, enhances performance of learning tasks in normal and amnestic rodents. Biochem Pharmacol Behav 1989; 34: 823-828.
36. Rosse RB, Schwartz BL, Davis RE, Deutsch SI. An NMDA intervention strategy in schizophrenia with ''low dose'' milacemide. Clin Neuropharmacol 1991; 14: 268-272.
37. Rosse RB, Schwartz BL, Leighton MP, et al. An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmacol 1990; 13: 348-354.
38. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005; 72: 225-234.
39. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59: 230-234.
40. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57: 577-585.
41. Tsai G, Yang P, Chung L-C, et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-1089.
42. Goff D, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psych 1999; 56: 21-27.
43. Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 2005; 179: 144-150.
44. Goff D, Henderson D, Evins A, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512-514.
45. Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-1602.
46. Carlsson ML, Martin P, Nilsson M, et al. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist-than dopamine agonist-induced hyperactivity in mice. J Neural Transm 1999; 106: 123-129.
47. Ninan I, Jardemark KE, Wang RY. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex. Neuropharmacology 2003; 44: 462-472.
48. Breese GR, Knapp DJ, Moy SS. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 2002; 26: 441-455.
49. D'Souza DC, Radhakrishnan R, Perry E, et al. Feasibility, safety, and efficacy of the combination of d-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology 2013; 38: 492-503.
50. Weiser M, Heresco-Levy U, Davidson M, et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry 2012; 73: e728-e734.
51. Kantrowitz JT, Malhotra D, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121: 125-130.
52. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 2009; 12: 468-478.
53. Bergeron R, Meyer T, Coyle J, Greene R.Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 1998; 95: 15730-15734.
54. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-649.
55. Tsai G, Lane HY, Yang P, et al.Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-456.
56. Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebocontrolled study. Arch Gen Psychiatry 2005; 62: 1196-1204.
57. Martin-Facklam M, Pizzagalli F, Zhou Y, et al. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology 2013; 38: 504-512.
58. Umbricht D, Alberati D, Martin-Facklam M, et al. A randomized, double-blind, proof-of-concept study of the effect of bitopertin, a glycine reuptake 2 inhibitor, on negative symptoms of schizophrenia. JAMA Psychiatry 2014; 71: 637-646.
59. Poels EM, Kegeles LS, Kantrowitz JT, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014; 19: 20-29.
60. Fusar-Poli P, Stone JM, Broome MR, et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry 2011; 68: 881-890.
61. Kraguljac NV, White DM, Reid MA, Lahti AC. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013; 70: 1294-1302.
62. Schobel SA, Chaudhury NH, Khan UA, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013; 78: 81-93.
63. Labrie V, Roder JC. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev 2010; 34: 351-372.
64. Sacchi S, Bernasconi M, Martineau M, et al. pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility. J Biol Chem 2008; 283: 22244-22256.
65. Lane HY, Lin CH, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013; 70: 1267-1275.
66. Xia M, Liu Y, Figueroa DJ, et al. Characterization and localization of a human serine racemase. Brain Res Mol Brain Res 2004; 125: 96-104.
67. Rutter AR, Fradley RL, Garrett EM, et al. Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. Eur J Neurosci 2007; 25: 1757-1766.
68. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64: 361-368.
69. Carmeli C, Knyazeva MG, Cuenod M, Do KQ. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PloS One 2012; 7: e29341.
70. Baker DA, Madayag A, Kristiansen LV, et al. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 2008; 33: 1760-1772.
71. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004; 4: 12-17.
72. Pellicciari R, Rizzo RC, Costantino G, et al. Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem 2006; 1: 528-531.
73. Potter MC, Elmer GI, Bergeron R, et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 2010; 35: 1734-1742.
74. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 2006; 60: 369-375.
75. Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005; 83: 224-231.
76. Quartermain D, Mower J, Rafferty MF, et al. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharm 1994; 257: 7-12.
77. Nong Y, Huang YQ, Ju W, et al. Glycine binding primes NMDA receptor internalization. Nature 2003; 422: 302-307.
78. Dravid SM, Burger PB, Prakash A, et al. Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci 2010; 30: 2741-2754.
79. Beneyto M, Meador-Woodruff JH. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008; 33: 2175-2186.
80. Langton JM, Richardson R. D-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 2008; 33: 3096-3102.
81. Goff DC, Cather C, Gottlieb JD, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106: 320-327.
82. Cain CK, McCue M, Bello I, et al. D-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr Res 2014; 153: 177-183.
83. Goff DC. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull 2012; 38: 936-941.
84. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-352.
85. Moskal JR, Burch R, Burgdorf JS, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 2014; 23: 243-254.
86. Mullasseril P, Hansen KB, Vance KM, et al. A subunit-selective potentiator of NR2C-and NR2D-containing NMDA receptors. Nat Commun 2010; 1: 90.
87. Suryavanshi PS, Ugale RR, Yilmazer-Hanke D, et al. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. Br J Pharmacol 2014; 171: 799-809.
88. Curley AA, Eggan SM, Lazarus MS, et al. Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia. Neurobiol Dis 2013; 50: 179-186.
89. Grunze HC, Rainnie DG, Hasselmo ME, et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034-2043.
90. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13: 1102-1107.
91. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatmentresistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54: 1241-1248.
92. Stauffer VL, Millen BA, Andersen S, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 2013; 150: 434-441.
93. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007; 27: 582-589.
94. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapineresistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009; 109: 10-14.
95. Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. Neuron 2013; 80: 704-717.
96. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Ann Rev Neurosci 2002; 25: 103-126.
97. Katayama T, Jodo E, Suzuki Y, et al. Activation of medial prefrontal cortex neurons by phencyclidine is mediated via AMPA/kainate glutamate receptors in anesthetized rats. Neuroscience 2007; 150: 442-448.
98. Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets 2007; 8: 583-602.
99. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-487.
100. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008; 33: 465-472.
101. Ayoub MA, Angelicheva D, Vile D, et al. Deleterious GRM1 mutations in schizophrenia. PloS One 2012; 7: e32849.
102. Matosin N, Newell KA. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci Biobehav Rev 2013; 37: 256-268.
103. Loane DJ, Stoica BA, Pajoohesh-Ganji A, et al. Activation of metabotropic glutamate receptor 5 modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase. J Biol Chem 2009; 284: 15629-15639.
104. Ayala JE, Chen Y, Banko JL, et al. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009; 34: 2057-2071.
105. Newell KA, Matosin N. Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry 2014; 14: 23.
106. Donohoe G, Walters J, Morris DW, et al. Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Arch Gen Psychiatry 2009; 66: 1045-1054.
107. O'Connor MI, Piehler MF, Leech DM, et al. Warming and resource availability shift food web structure and metabolism. PLoS Biol 2009; 7: e1000178.
108. Wratten NS, Memoli H, Huang Y, et al. Identification of a schizophreniaassociated functional noncoding variant in NOS1AP. Am J Psychiatry 2009; 166: 434-441.
109. Hallak JE, Maia-de-Oliveira JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013; 70: 668-676.
110. Reneerkens OA, Rutten K, Steinbusch HW, et al. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 2009; 202: 419-443.
111. Saavedra A, Giralt A, Arumi H, et al. Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease. PloS One 2013; 8: e73664.
112. Wang C, Zhang J, Lu Y, et al. Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling in mice. Metab Brain Dis 2014; 29: 673-682.
113. Agostino PV, Plano SA, Golombek DA. Sildenafil accelerates reentrainment of circadian rhythms after advancing light schedules. Proc Natl Acad Sci USA 2007; 104: 9834-9839.
114. Rodefer JS, Saland SK, Eckrich SJ. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2012; 62: 1182-1190.
115. Akhondzadeh S, Ghayyoumi R, Rezaei F, et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology 2011; 213: 809-815.
116. Goff DC, Cather C, Freudenreich O, et al. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology 2009; 202: 411-417.
117. Siuciak JA. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 2008; 22: 983-993.
118. Heckman PR, Blokland A, Ramaekers J, Prickaerts J. PDE and cognitive processing: beyond the memory domain. Neurobiol Learn Mem 2014. [Epub ahead of print]